TIGIT Blockade and IL15 in Tumor Immunotherapy: Together is Better
Overview
Affiliations
IL15 and TIGIT blockade enhances the natural killer (NK) cell-mediated activity against MHC-I-deficient melanoma both and in preclinical models. IL15-induced harnessing of NK cells, associated with their unleashing by TIGIT blockade, may represent a therapeutic approach for tumors, which lack HLA-I molecules thus escaping the CD8 T cell-mediated control..
Targeting TIGIT for cancer immunotherapy: recent advances and future directions.
Zhang P, Liu X, Gu Z, Jiang Z, Zhao S, Song Y Biomark Res. 2024; 12(1):7.
PMID: 38229100 PMC: 10790541. DOI: 10.1186/s40364-023-00543-z.
The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients.
Pawlowska A, Skiba W, Suszczyk D, Kurylo W, Jakubowicz-Gil J, Paduch R Cancers (Basel). 2022; 14(23).
PMID: 36497240 PMC: 9740841. DOI: 10.3390/cancers14235757.
Grottoli M, Carrega P, Zullo L, Dellepiane C, Rossi G, Parisi F Cancers (Basel). 2022; 14(20).
PMID: 36291830 PMC: 9599824. DOI: 10.3390/cancers14205046.
Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets.
Zhou X, Ren T, Zan H, Hua C, Guo X Front Immunol. 2022; 13:864202.
PMID: 35669786 PMC: 9163322. DOI: 10.3389/fimmu.2022.864202.